Home / Compounds / Orforglipron
Orforglipron
Non-peptide GLP-1 receptor agonist · Foundayo in the United States. No UK brand name yet
- UK status
- Not licensed in the UK
- Availability
- Not available in the UK
- Evidence base
- Human RCT, phase 3
- Controlled drug
- No
Sequence
Not a peptide. A small molecule, so there is no amino acid sequence.
Orforglipron matters for one structural reason: it does the same job as the GLP-1 injections but it is not built from amino acids. That single difference is why it can be swallowed.
01What it is
Every GLP-1 drug before it was a peptide, and peptides are destroyed by the digestive system. That is why Wegovy and Mounjaro are injections. Oral semaglutide gets around the problem with an absorption enhancer and strict rules about taking it on an empty stomach.
Orforglipron takes a different route. It is a small molecule, conventional drug chemistry rather than a copy of a hormone, designed to activate the same GLP-1 receptor. Being a small molecule means it survives the stomach on its own, needs no food or water restrictions, and is far easier to manufacture at scale.
Because it is the clearest illustration of what the word peptide does and does not tell you. Orforglipron is not a peptide but does the same thing as one. BPC-157 is a peptide and does nothing that has been demonstrated in humans. Structure is not function.
02UK legal and licensing status
Orforglipron has no MHRA marketing authorisation. It cannot be lawfully prescribed or supplied in the UK, on the NHS or privately. Any UK-facing site offering it is operating outside the law, and because the Yellow Card scheme covers licensed medicines, a safety problem arising from an unlicensed import would not be captured by it.
The FDA approved it on 1 April 2026 in the United States, marketed as Foundayo. The manufacturer has submitted it for approval in a large number of countries including the UK. Public expectations put a UK decision around late 2026 or into 2027, with any NHS availability following a separate NICE appraisal after that.
Timelines from company statements and press coverage are estimates, not commitments. Check the MHRA for the actual decision rather than relying on any predicted date, including this one.
03How it works
It binds and activates the GLP-1 receptor, producing the same three effects as the injectable GLP-1 drugs.
- Glucose-dependent insulin release. More insulin when blood glucose is raised.
- Slower gastric emptying. Fullness lasts longer after eating.
- Reduced appetite signalling. Acting on the brain rather than the gut.
- Once daily, any time. No fasting window, unlike oral semaglutide. In practical terms this is the main advantage people care about.
04What the evidence shows
Phase 3 results reported average weight reduction in the region of 11 to 12 per cent of body weight over 72 weeks at the highest dose studied. Reported side effects followed the class pattern and were described as mostly mild to moderate and gastrointestinal.
Worth being precise about the comparison, because it is routinely overstated in both directions. On the published figures orforglipron produces less weight change than tirzepatide at its top dose, and roughly comparable or slightly more than oral semaglutide. The case for it is access, convenience and manufacturing scale, not maximum effect.
The ATTAIN-MAINTAIN trial, published in Nature Medicine in 2026, looked at whether weight reduction is maintained when people switch from an injectable GLP-1 to orforglipron.
No UK regulatory assessment has happened, so there is no SPC, no MHRA-approved patient information and no NICE view. Long-term data is still accumulating, as with everything in this class.
05Reported harms
Trial reporting describes the familiar gastrointestinal pattern: nausea, vomiting, diarrhoea and constipation. Because there is no UK licence there is no Summary of Product Characteristics, and therefore no authoritative frequency table for a UK reader.
The class-wide practical points still apply and are worth raising with a prescriber if it is ever licensed here: additional contraception alongside the oral contraceptive pill, and telling the anaesthetist before any procedure.
06Sources
Links go to the primary source. Where a source is behind a paywall or requires registration, the citation is given so you can find it yourself.
- First GLP-1 tablet for weight loss approved in the UKMHRA, June 2026, for context on the oral class
- Orforglipron for maintenance of body weight reduction, ATTAIN-MAINTAINNature Medicine, 2026
- Phase 3 trial recordsClinicalTrials.gov
- Buying medicines onlineMHRA
- Technology appraisalsNICE
07Change history
Every substantive change to this record is logged here with its date. Corrections are made openly, not quietly.
Loading…
Want telling when this record changes? Follow it from your account.